Uri Galili is an immunologist who received his PhD in 1977 at the Hebrew University School of Medicine, Jerusalem, Israel. After working at Hadassah University Hospital, Jerusalem (1979-1984) where he discovered anti-Gal as the most abundant natural antibody in humans, he worked at University of California Medical Center, San Francisco (1984-1990), where he identified the α-gal epitope as the mammalian antigen binding anti-Gal, determined the unique evolution of anti-Gal and a-gal epitopes in primates and studied the molecular basis for this evolution. In subsequent years he worked at MCP-Hahnemann School of Medicine, Philadelphia (1991-1999), Rush Medical school, Chicago (1999-2004) and UMass Medical School, Worcester (2004-2013) as a professor, and developed methods harnessing the anti-Gal antibody for performing several therapies including: cancer immunotherapy, increased vaccine immunogenicity, acceleration of wound and burn healing, and inducing tissue regeneration. Dr. Galili retired in 2013 and lives in Chicago. He continues his research as volunteering Adjunct Professor at Rush Medical School, where he studies regeneration in ischemic myocardium, post myocardial infarction and in other tissues, by a-gal nanoparticles. In 2017 Dr. Galili published the book he wrote “The Natural Anti-Gal Antibody as Foe Turned Friend in Medicine” (Academic Press/Elsevier publishers), which reviews immunological, evolutionary, pathological and therapeutic studies on the natural anti-Gal antibody.